Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

NCT02017327 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

379

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Monoprost
DRUG: Lumigan 0.01%
DRUG: Lumigan 0.03% Unit Dose

Sponsor

Laboratoires Thea